Form 8-K ELITE PHARMACEUTICALS For: Jun 29

Mon, 29 Jun 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260629/26707273.html

Form 8-K ELITE PHARMACEUTICALS For: Jun 29

Mon, 29 Jun 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260629/26707273.html

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information

Mon, 29 Jun 2026 16:29:00 -0400

Conference Call Scheduled for Tuesday, June 30 at 11:30 AM EDT

Northvale, New Jersey--(Newsfile Corp. - June 29, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2026 ("Fiscal 2026").

Consolidated revenues for Fiscal 2026 were $148.9 million, an increase of $64.8 million or approximately 77% as compared to the comparable period of the prior fiscal year. Income from operations was $49.1 million, an increase of $29.5 million or approximately 151% from the comparable period of the prior year. The increase in income from

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information

Mon, 29 Jun 2026 16:29:00 -0400

Conference Call Scheduled for Tuesday, June 30 at 11:30 AM EDT

Form 10-K ELITE PHARMACEUTICALS For: Mar 31

Mon, 29 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260629/26706444.html

Form 10-K ELITE PHARMACEUTICALS For: Mar 31

Mon, 29 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260629/26706444.html

Form 8-K ELITE PHARMACEUTICALS For: Jun 23

Tue, 23 Jun 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260623/26675732.html

Form 8-K ELITE PHARMACEUTICALS For: Jun 23

Tue, 23 Jun 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260623/26675732.html

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results on June 30, 2026

Tue, 23 Jun 2026 07:00:00 -0400

Financials for Fiscal Year 2026 Ended March 31, 2026 will be released on Monday, June 29, 2026

Northvale, New Jersey--(Newsfile Corp. - June 23, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it will release its 2026 year-end financial results on Monday, June 29, 2026. Elite's management will host a live conference call on Tuesday, June 30^th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update. Stockholders should submit questions to the company before the call.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results on June 30, 2026

Tue, 23 Jun 2026 07:00:00 -0400

Financials for Fiscal Year 2026 Ended March 31, 2026 will be released on Monday, June 29, 2026

Elite Pharmaceuticals completes bioequivalence study for anticonvulsant

Mon, 15 Jun 2026 07:03:44 -0400

Elite Pharmaceuticals Inc. (OTCQB: ELTP) reported positive results from a bioequivalence study for an undisclosed anticonvulsant generic drug product, according to a company statement.

The study demonstrated that Elite's generic product is bioequivalent to the branded version. IQVIA reported that branded and generic product sales for this anticonvulsant totaled $840 million for the twelve months ending April 2026.

The bioequivalence studies were conducted as open-label, randomized, balanced, single oral dose, two-treatment, two-period, two-sequence, crossover studies in healthy adult subjects under fasting conditions. Elite is preparing data from the study to file an Abbreviated New Drug Application with the U.S. Food and Drug

Form 8-K ELITE PHARMACEUTICALS For: Jun 15

Mon, 15 Jun 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260615/26644116.html

Form 8-K ELITE PHARMACEUTICALS For: Jun 15

Mon, 15 Jun 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260615/26644116.html

Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study

Mon, 15 Jun 2026 07:00:00 -0400

Northvale, New Jersey--(Newsfile Corp. - June 15, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today reported positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic drug product.

IQVIA reported branded and generic product sales for the twelve months ending April 2026 of $840 million.

The studies conducted were open-label, randomized, balanced, single oral dose, two-treatment, two-period, two-sequence, crossover bioequivalence studies in normal, healthy, adult, human subjects under fasting conditions. The results indicated that the generic product is bioequivalent to

Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study

Mon, 15 Jun 2026 07:00:00 -0400

IQVIA reported branded and generic product sales for the twelve months ending April 2026 of $840 million.

Form 8-K ELITE PHARMACEUTICALS For: May 29

Mon, 01 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260601/26578926.html

Form 8-K ELITE PHARMACEUTICALS For: May 29

Mon, 01 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260601/26578926.html

Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product

Mon, 01 Jun 2026 07:00:00 -0400

Northvale, New Jersey--(Newsfile Corp. - June 1, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for a generic drug product in the class of medications called anticoagulants.

IQVIA reported branded product sales for the twelve months ending March 2026 of $26 billion. There is no generic product on the market, and the brand has unexpired patents and exclusivity listed in the FDA's Approved Drug

Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product

Mon, 01 Jun 2026 07:00:00 -0400

Form 8-K ELITE PHARMACEUTICALS For: Apr 02

Thu, 02 Apr 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260402/26262883.html

Form 8-K ELITE PHARMACEUTICALS For: Apr 02

Thu, 02 Apr 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260402/26262883.html

Elite Pharmaceuticals launches generic methadone tablets

Thu, 02 Apr 2026 08:01:11 -0400

Elite Pharmaceuticals Inc. (OTCQB: ELTP) announced the commercial launch of its generic methadone hydrochloride tablets in 5 mg and 10 mg strengths.

The tablets are indicated for managing severe and persistent pain requiring opioid analgesics when alternative treatment options, including immediate-release opioids, are inadequate. The medication is also approved for detoxification and maintenance treatment of opioid addiction when used with appropriate social and medical services.

According to IQVIA data cited by the company, brand and generic methadone products generated approximately $22 million in annual retail sales in 2025.

Elite Pharmaceuticals operates as a specialty pharmaceutical company focused on developing and distributing niche generic

Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets

Thu, 02 Apr 2026 08:00:00 -0400

Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of methadone hydrochloride 5 mg and 10 mg tablets. Methadone tablets are indicated for the management of severe and persistent pain that requires an opioid analgesic that cannot be adequately treated with alternative options including immediate-release opioids. Methadone can also be used for detoxification treatment of opioid addiction (heroin or other morphine-like drugs) and for maintenance treatment of opioid addiction (heroin or other morphine-like

Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets

Thu, 02 Apr 2026 08:00:00 -0400

Form 8-K ELITE PHARMACEUTICALS For: Feb 17

Tue, 17 Feb 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260217/26015005.html

StreetInsider.com News Articles

Form 8-K ELITE PHARMACEUTICALS For: Jun 29

Form 8-K ELITE PHARMACEUTICALS For: Jun 29

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information

Form 10-K ELITE PHARMACEUTICALS For: Mar 31

Form 10-K ELITE PHARMACEUTICALS For: Mar 31

Form 8-K ELITE PHARMACEUTICALS For: Jun 23

Form 8-K ELITE PHARMACEUTICALS For: Jun 23

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results on June 30, 2026

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results on June 30, 2026

Elite Pharmaceuticals completes bioequivalence study for anticonvulsant

Form 8-K ELITE PHARMACEUTICALS For: Jun 15

Form 8-K ELITE PHARMACEUTICALS For: Jun 15

Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study

Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study

Form 8-K ELITE PHARMACEUTICALS For: May 29

Form 8-K ELITE PHARMACEUTICALS For: May 29

Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product

Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product

Form 8-K ELITE PHARMACEUTICALS For: Apr 02

Form 8-K ELITE PHARMACEUTICALS For: Apr 02

Elite Pharmaceuticals launches generic methadone tablets

Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets

Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets

Form 8-K ELITE PHARMACEUTICALS For: Feb 17